Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The US Food and Drug Administration (FDA) has approved GSK’s depemokimab-ulaa (Exdensur

 as an add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in adult and pediatric patients ≥ 12 years of age.

As described in a December 16, 2025, release from the Company, the decision was based on data from the phase 3 SWIFT-1 and SWIFT-2 trials showing sustained exacerbation reduction with 2 doses per year versus placebo, both plus standard of care.

“Current biologic treatments for asthma are often underutilised and frequent injections can be inconvenient for many patients and lead to inconsistent use. There is clearly an opportunity to provide a longer duration of protection from exacerbations between injections for severe asthma patients that reduces the frequency of doses and may improve overall health care utilisation,” Geoffrey Chupp, MD, Professor of Medicine, Pulmonary, Critical Care and Sleep Medicine, Yale University, said in a statement.

could empower physicians and patients to potentially achieve their treatment goals with fewer injections.”

Depemokimab-ulaa is the first ultra-long-acting biologic being evaluated for certain respiratory diseases with underlying type 2 inflammation, such as severe asthma. It has been developed with an extended half-life to enable twice-yearly dosing.

SWIFT-1 and SWIFT-2 assessed the efficacy and safety of depemokimab adjunctive therapy in 382 and 380 participants with severe asthma who were randomly assigned to receive depemokimab or a placebo respectively, in addition to their standard of care treatment with medium to high-dose inhaled corticosteroids plus ≥ 1 additional controller.

The full analysis set in SWIFT-1 included 250 patients in the depemokimab plus standard of care arm and 132 in the placebo plus standard of care arm; in SWIFT-2, 252 patients were included in the depemokimab plus standard of care arm and 128 in the placebo plus standard of care arm.

Results showed treatment with depemokimab resulted in a significant 58% and 48% reduction in the rate of annualised asthma exacerbations (asthma attacks) over 52 weeks from SWIFT-1 and SWIFT-2, respectively (SWIFT-1: Rate ratio, 0.42; 95% CI, 0.30-0.59; 

<.001 and SWIFT-2: Rate ratio, 0.52; 95% CI, 0.36-0.73; 

<.001; AER depemokimab vs placebo: SWIFT-1 0.46 vs 1.11 and SWIFT-2 0.56 vs 1.08 exacerbations per year).

In a secondary endpoint from SWIFT-1 and SWIFT-2, patients treated with depemokimab experienced numerically fewer exacerbations requiring hospitalization and/or emergency department visits (1% and 4%) compared with placebo (8% and 10%), respectively. A pre-specified pooled analysis of the trials showed a 72% reduction in the annualized rate of clinically significant exacerbations requiring hospitalisation and/or ED visits over 52 weeks for depemokimab compared with placebo (rate ratio, 0.28; 95% CI, 0.13-0.61; nominal 

= .002; AER depemokimab 0.02 vs placebo 0.09).

Across these trials, depemokimab was well-tolerated, with patients experiencing a similar rate and severity of side effects as those receiving placebo.

“The struggle for people living with severe asthma is immense, with many silently enduring continued symptom recurrence and exacerbations. An innovative treatment option like Exdensur that offers the long-acting protection from exacerbations that severe asthma patients with an eosinophilic phenotype deserve, with the benefit of fewer doses, is truly welcome,” Tonya Winders, President and CEO, Global Allergy & Airways Patient Platform, said.

GSK. Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma. December 16, 2025. Accessed December 16, 2025. 

https://www.gsk.com/en-gb/media/press-releases/exdensur-depemokimab-approved-by-us-fda-for-the-treatment-of-severe-asthma/

Smith T. Positive Phase 3 Findings Identified for Depemokimab Treatment of Severe Asthma. September 9, 2024. Accessed December 16, 2025. 

https://www.hcplive.com/view/positive-phase-3-findings-identified-depemokimab-treatment-severe-asthma

Articles

The FDA has approved GSK's depemokimab-ulaa (Exdensur) for severe asthma with an eosinophilic phenotype in patients aged 12 and older. This approval is based on phase 3 SWIFT-1 and SWIFT-2 trials, which demonstrated significant reductions in asthma exacerbations with twice-yearly dosing. Depemokimab-ulaa, an ultra-long-acting biologic, showed a 58% and 48% reduction in exacerbation rates in SWIFT-1 and SWIFT-2, respectively. The treatment was well-tolerated, with fewer exacerbations requiring hospitalization or emergency visits compared to placebo, offering a promising option for severe asthma management.

Depemokimab-ulaa is the first and only ultra-long-acting biologic with twice-yearly dosing for patients with severe asthma with an eosinophilic phenotype.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

FDA News

FDA Approves Depemokimab-ulaa (Exdensur) for Severe Asthma

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Credit: Norwegian University of Science and Technology

A study found that participants with moderate or severe 

had a significantly reduced ability to relax their muscles compared with those reporting minimal or no chronic pain.

“The results of this study may have value for clinical practice by increasing the attention, awareness, and evidence of the ability to relax muscles and highlight that clinical bodily findings among individuals with chronic pain should guide the choice of treatment,” wrote investigator Live Førland Havstad, PhD Candidate, from Norwegian University of Science and Technology, and colleagues.

Clinicians commonly assess muscle tension by evaluating a patient’s ability to relax through flexibility testing and passive range-of-motion maneuvers. Clinicians may measure muscle displacement, force, and stiffness.

Empirical evidence characterizing muscle tension in patients with chronic pain remains limited. Thus, investigators compared the ability to relax muscles in individuals with and without chronic pain, as well as in those with fibromyalgia and chronic tension-type headache, versus other chronic pain conditions.

The team analyzed data from the HUNT Pain Examination Study, which included 551 individuals from the general Norwegian population. Based on clinical assessments by physicians and physiotherapists, 399 participants had chronic pain of at least moderate severity, while 152 had no chronic pain. Among those with chronic pain, 57 had fibromyalgia, and 23 had chronic tension-type headache.

Investigators evaluated muscle relaxation using the Global Physiotherapy Examination (GPE), which assesses flexibility and passive movement. Investigators performed multiple linear regression analyses to examine associations between chronic pain status and the ability to relax muscles.

Results showed that participants with moderate to severe chronic pain had significantly poorer muscle relaxation, reflected by reduced flexibility (

 < .001) and impaired passive movements (

< .001), compared with those with minimal or no chronic pain. Gender, age, and chronic pain status accounted for 23% of the variance in flexibility and 15% of the variance in passive movements. Women demonstrated a greater ability to relax their muscles than men. Further analyses demonstrated reductions in flexibility and passive movements among participants with fibromyalgia (

 <.001) and chronic tension-type headache (

=.027) compared with those with other chronic pain conditions.

The team noted the absence of a clear definition for what constitutes a normal ability to relax muscles. In prior research, GPE testing in healthy individuals who struggled with muscle relaxation helped distinguish deviations from an “ideal” ability versus a normal range. The investigators emphasized the need to establish normative ranges and clinically meaningful thresholds, which could inform decisions about whether improving muscle relaxation should serve as a treatment target.

Investigators acknowledged several limitations, including the use of the broad term of flexibility. In this study, flexibility represented the participant’s ability to relax muscles, but the term also captures joint mobility and may relate to limitations in connective tissue elasticity involving joint capsules, tendons, and ligaments. Age-related changes in joint mobility further complicate interpretation, making it difficult to determine whether reduced flexibility stemmed from biomechanical joint constraints, impaired muscle relaxation, or both.

Additional limitations included an older sample (mean age, 63 years) and potential bias from subjective assessments conducted by multiple examiners, without intra-examiner reliability testing. The findings were also influenced by the HUNT study’s 52% participation rate. Participants were drawn from HUNT-3, which included lower proportions of men, younger individuals, and those with lower socioeconomic status, along with higher rates of musculoskeletal pain and headache.

“The findings reveal a significant reduction in the ability to relax muscles during clinical testing in these patient groups,” investigators concluded. “This contribution from the general population provides insights into an area often studied within patient populations, underlining the importance of relaxation techniques as a component in the management of chronic pain.”

Havstad LF, Glette M, Landmark T, Butler S, Woodhouse A. The Ability to Relax Muscles in Chronic Pain Conditions in the General Population: A Cross-Sectional Study (The HUNT Pain Examination Study). 

. 2026;31(1):e70131. doi:10.1002/pri.70131

Davidson MJ, Nielsen PMF, Taberner AJ, Kruger JA. Is it time to rethink using digital palpation for assessment of muscle stiffness?. 

. 2020;39(1):279-285. doi:10.1002/nau.24192

A study involving 551 participants from the Norwegian population revealed that individuals with moderate to severe chronic pain exhibit significantly reduced muscle relaxation capabilities compared to those with minimal or no pain. The research utilized the Global Physiotherapy Examination to assess flexibility and passive movement, finding notable impairments in those with fibromyalgia and chronic tension-type headache. The study highlights the need for establishing normative ranges for muscle relaxation and suggests that improving muscle relaxation could be a treatment target. Limitations include potential biases and the broad definition of flexibility.

New data links chronic pain to impaired muscle relaxation, with the greatest limitations observed in fibromyalgia and chronic tension-type headache.

Pain

The HCPLive pain page is a resource for medical news and expert insights on pain medicine. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for acute pain, chronic pain, addiction medicine, and more.

Chronic Pain

On the HCPLive chronic pain page, resources on the topics of medical news and expert insight into pain treatment can be found. Content includes articles, interviews, videos, podcasts, and breaking news on chronic pain, and more.

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Fibromyalgia

On the HCPLive fibromyalgia page, resources on the topics of medical news and expert insight into fibrositis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on fibromyalgia, and more.

Chronic Pain Associated With Significantly Reduced Ability to Relax Muscles

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Skin of Color Savvy: The Art and Science of Treating Patients of Color

Welcome to Skin of Color Savvy: The Art and Science of Treating Patients of Color!

In this 'Savvy Conversations' episode of 

, hosted by Skin of Color Society leaders and produced by 

, Heather Woolery-Lloyd, MD, an internationally recognized expert in skin of color, board-certified dermatologist at Miami Design District Dermatology and Aesthetics, and director of Ethnic Skin Care at the University of Miami Department of Dermatology and Cutaneous Surgery, sits down with Aderonke Obayomi, MD, MPH, a board-certified dermatologist at Mount Sinai Health System, for an in-depth discussion on 

 and seasonal dermatologic challenges affecting patients of color.

Drawing from their experiences practicing in very different climates, Woolery-Lloyd and Obayomi explore how seasonal changes, particularly decreased humidity, can significantly impact skin health. Obayomi, who trained in Miami before relocating to New York, describes the stark contrast in patient presentations, noting increased severity of xerosis, eczema flares, and pruritus in colder environments where indoor heating further dries the air. The conversation highlights how environmental factors such as forced indoor heat, limited control over apartment temperatures, and prolonged cold exposure can exacerbate inflammatory skin conditions.

The episode offers practical, evidence-based guidance for clinicians counseling patients during winter months. Obayomi emphasizes foundational skincare strategies, including the use of humidifiers, transitioning from lotions to thicker creams or ointments, avoiding prolonged hot showers, and moisturizing immediately after bathing. Both dermatologists stress the importance of barrier repair and frequent reapplication, reinforcing that during winter months, aggressive moisturization is often necessary to maintain skin integrity.

Woolery-Lloyd expands the discussion to include how winter affects chronic dermatologic conditions such as eczema, psoriasis, and acne. They review clinical observations and data suggesting that while some patients experience minimal seasonal variation, others see meaningful worsening during colder months, likely driven by barrier dysfunction, reduced humidity, and lifestyle factors including stress and holiday-related dietary changes. The conversation underscores the importance of individualized patient counseling and anticipatory guidance.

A key focus of the episode is how winter skin conditions may present differently in patients of color. Obayomi explains that erythema can be subtler or present as violaceous, gray, or ashy tones, and that follicular eczema is more commonly observed. Both dermatologists emphasize that post-inflammatory hyperpigmentation is a frequent and often distressing sequela of inflammation in skin of color, reinforcing the importance of early intervention and control of the underlying condition.

The conversation also addresses common misconceptions around skincare practices, including reliance on natural oils, essential oils, and homemade remedies, which may worsen irritation or provoke allergic reactions. Woolery-Lloyd and Obayomi stress the importance of gentle, fragrance-free formulations and caution against assuming that “natural” products are inherently safe.

Finally, the episode reinforces the year-round importance of sunscreen use, particularly tinted mineral sunscreens containing iron oxides, to protect against UVA and visible light, both of which contribute to pigmentary disorders in skin of color. Together, Woolery-Lloyd and Obayomi deliver a clinically grounded, culturally informed discussion that equips clinicians with practical strategies to better care for patients of color throughout the winter season.

To learn more about SOCS’s mentorship programs and initiatives, visit 

Editor’s note: This summary was edited with the help of artificial intelligence tools.

The discussion between dermatologists Heather Woolery-Lloyd and Aderonke Obayomi focuses on the unique dermatologic challenges faced by patients of color during winter. They explore how decreased humidity and environmental factors exacerbate conditions like xerosis, eczema, and pruritus. Practical skincare strategies, such as using humidifiers and thicker creams, are emphasized. The conversation highlights the importance of individualized patient counseling, especially regarding post-inflammatory hyperpigmentation and the subtler presentation of erythema in skin of color. The episode also addresses misconceptions about natural skincare products and underscores the importance of sunscreen use.

This December 16 episode features a discussion of winter skin concerns and seasonal dermatologic challenges impacting patients with skin of color.

Hosted by Skin of Color Society and produced by HCPLive, 

 delves into the latest research, clinical insights, and culturally intelligent care practices in dermatology with leading experts. 

Whether it’s groundbreaking research, practice-changing insights, or highlights from the SOCS community, this twice-monthly program provides dermatologists and care providers with expert perspectives on treating patients with skin of color.

Podcasts

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Videos

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Skin of Color Savvy: Winter Skin Care for Patients of Color, With Heather Woolery-Lloyd, MD, and Aderonke Obayomi, MD, MPH

Lynn Malec, MD, MSc, is an associate professor in the division of hematology and oncology at the Medical College of Wisconsin.

Efanesoctocog Alfa Improves Bleeding Regardless of Age in Hemophilia A, With Lynn Malec, MD, MSc

Once-weekly efanesoctocog alfa is both well tolerated and efficacious in providing bleed protection to adult, adolescent, and child patients with 

, according to results from the XTEND-ed study.

 67th American Society of Hematology (ASH) Annual Meeting and Exposition

 by Lynn Malec, MD, MSc, an associate professor in the division of hematology and oncology at the Medical College of Wisconsin.

Efanesoctocog alfa is a first-in-class high-sustained factor VIII (FVIII) replacement therapy that decouples recombinant FVIII from endogenous von Willebrand factor. The prior phase 3 XTEND-1 and XTEND-Kids studies saw once-weekly efanesoctocog alfa exhibit effective bleed protection and provide FVIII activity within the normal to near-normal (>40%) range for 4 and 3 days, respectively, at steady state.

“I think the exciting data, besides just the aspects of the inhibitors, is how well patients are protected from bleeding,” Malec told 

 in an exclusive interview. “We typically measure that by way of annualized bleed rates in patients, and what we saw in the study was that patients across the age span continue to have really great bleed protection while on the extension study.”

Participants who completed the XTEND-1 or XTEND-Kids study could continue once-weekly 50 IU/kg of efanesoctocog alfa prophylaxis in XTEND-ed, an ongoing multicenter, open-label, long-term study. The primary endpoint for this trial was incidence of FVIII inhibitor development, while secondary endpoints included annualized bleed rates (ABRs), efficacy for bleed treatment, and safety.

Ultimately, 146 adult and adolescent patients rolled over from the XTEND-1 to XTEND-ed baseline. The median age was 37 years (range, 13-74), and the median treatment duration in XTEND-ed was 166 weeks (range, 14.1-192.7), which comprised a median of 167 days (range, 14-200) exposure days (EDs).

During the trial, the mean ABR for day 1-month 12 (n = 146) was 0.7 (standard deviation [SD], 1.31), months 12-24 (n = 141) was 0.62 (1.23), and months 24-36 (n = 132) was 0.45 (1.24), with 96/146 (65.8%), 96/141 (68.1%), and 103/132 (78%) of participants with zero bleeds, respectively. The mean model-based ABR for the efficacy period was 0.6 (95% CI, 0.47-0.76) for overall treated bleeds, and 0.2 (95% CI, 0.15-0.28) and 0.29 (95% CI, 0.22-0.39) for spontaneous and traumatic bleeds, respectively. Additionally, of 252 treated bleeding episodes, 94% were resolved with 1 efanesoctocog alfa injection.

Among children, 71 patients rolled over from XTEND-kids to XTEND-ed; median treatment duration was 116.7 (range, 36.3-152.6) weeks, comprising a median of 116 (range, 11-153) EDs. The mean ABR evaluated for day 1-month 12 (n = 71) was 0.68 (SD, 1.13) and months 12-25 (n = 62) was 0.49 (0.82), with 46/71 (64.8%) and 41/62 (66.1%) of participants with zero bleeds, respectively. The mean model-based ABR was 0.64 (95% CI, 0.48-0.85) for overall treated bleeds, and 0.08 (95% CI, 0.04-0.15) and 0.44 (95% CI, 0.31-0.62) for spontaneous and traumatic bleeds, respectively. Of 89 episodes, 91% (81) were resolved with 1 efanesoctocog injection. No FVIII inhibitors were noted in either the adult/adolescent or child groups at any point during the study.

“I treat patients across the age spectrum – both pediatric and adult patients – and I think the aspect of zero bleeds really is the new benchmark,” Malec told HCPLive. “Are you on a therapy to be bleed-free or to have zero bleeds? I think that data is, in my mind, the gold standard.”

Editor's Note: Malec reports disclosures with Biomarin, Genentech, Novo Nordisk, Sanofi, Shire, and Takeda, among others.

Susen S, Chan A, Chowdary P, et al. Clinical outcomes up to 4 years of once-weekly efanesoctocog alfa prophylaxis in previously treated adults, adolescents, and children with severe hemophilia A: Interim analysis of the phase 3 XTEND-ed long-term extension study. Abstract presented at the 67th American Society of Hematology Annual Meeting. Orlando, Fl. December 6-9, 2025.

Bioverativ. A phase 3 open-label interventional study of intravenous recombinant coagulation factor VIII fc-von Willebrand factor-XTEN fusion protein, efanesoctocog alfa (BIVV001) in patients with severe hemophilia A (XTEND-1). ClinicalTrials.gov Identifier: NCT04161495. Updated September 17, 2025. Accessed December 16, 2025. 

https://clinicaltrials.gov/study/NCT04161495

Malec discusses the XTEND-ed trial, which proved the efficacy and tolerability of efanesoctocog alfa in adults and children with hemophilia A.

Hematology

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

A recent analysis of global data suggest the reported prevalence of 

focal segmental glomerulosclerosis (FSGS)

 has increased over time in most countries.

With > 32 years of data, the findings provide clinicians with epidemiological information while establishing a foundation for future research to characterize geographic differences, temporal trends, and potential risk factors.

“This information is crucial for tailoring prevention strategies, refining diagnostic approaches, and guiding future research efforts aimed at addressing the global burden of FSGS,” wrote study investigator Venice Chávez-Valencia, from the Ambulatory Care Medical Unit 254 of the Mexican Social Security Institute, and colleagues.

Previous research has emphasized slowing disease progression as the primary therapeutic goal in FSGS, but beyond understanding the underlying pathologic mechanisms, improved characterization of geographic and population-level epidemiology may help inform disease recognition and management, particularly given the absence of an FDA-approved pharmacologic therapy for FSGS.

To address gaps in the literature, Chávez-Valencia and colleagues conducted a systematic review of studies published between 1992 and 2024 using the Medline, Embase, and ScienceDirect databases.

For inclusion, studies were required to be original research, published in English or Spanish, and to report epidemiological data on FSGS prevalence, incidence, or temporal trends. Exclusion criteria included duplicate publications, insufficient incidence or prevalence data, unavailable full text, incomplete datasets, reporting bias, review articles, transplant registries, conference abstracts, unpublished manuscripts, sample sizes <100 patients, and recurrent FSGS.

Investigators emphasized substantial heterogeneity across study designs regarding renal biopsy practices, which subsequently limited the comparability of this data.

After applying the eligibility criteria, investigators included 130 studies in the final analysis. Asia accounted for the largest number of reports (n = 67), followed by Europe (n = 33), the Americas (n = 22), and then Africa (n = 9).

Across regions, investigators observed substantial variability in reported prevalence, reflecting differences in study design, biopsy practices, and population characteristics rather than true population-level incidence. Together, South Asian and Middle Eastern cohorts had a mean prevalence of 19%, while there was 6.5% in East Asian cohorts.

In the Americas, several countries reported relatively increased estimates of FSGS rates. In the United States, investigators reported a mean estimate of approximately 20%. Comparisons between time periods, 1994–2003 and 2004–2013, suggested an increase in reported cases over time. In fact, 2 studies reported incidence estimates of approximately 1.6 cases per 100,000 individuals per year.

Investigators noted relatively similar prevalence rates between European countries, with an average of 10%. They also pointed out that several studies, particularly from Africa and parts of Asia, had an increased proportion of FSGS among pediatric patients, underscoring age-related differences in disease burden and diagnosis.

“It is important to note that data from many countries are based on limited samples, not numerically representative of the population, which means that actual prevalence rates of FSGS may differ from those reported,” concluded investigators. “Despite these limitations, this study provides valuable information on an estimate of the overall prevalence of FSGS in different countries and, in some cases, highlights trends and changes over time.”

Orizaga-de-la-Cruz C, Lagunas-Rangel FA, Gómez-García A, Chávez-Valencia V, et al. An approximation to the prevalence of focal segmental glomerulosclerosis: A systematic review of world literature over the past 32 years. 

https://doi.org/10.1016/j.nefroe.2025.501404

Abbate M, Zoja C, Remuzzi G. How Does Proteinuria Cause Progressive Renal Damage? Journal of the American Society of Nephrology. 2006;17(11):2974-2984. doi:

The prevalence of focal segmental glomerulosclerosis (FSGS) has reportedly increased globally over the past 32 years, with significant geographic variability. This data is crucial for developing prevention strategies, refining diagnostics, and guiding research. A systematic review of studies from 1992 to 2024 revealed substantial heterogeneity in study designs and biopsy practices, affecting data comparability. The analysis included 130 studies, with Asia contributing the most reports. Variability in prevalence was noted, with South Asian and Middle Eastern cohorts showing higher rates than East Asian cohorts. The study underscores the need for more representative data.

A review of 32 years of global data on FSGS highlights increased prevalence, with a limitation of biopsy variation and regional practices.


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Focal Segmental Glomerulosclerosis

The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more. 

Global Data Suggest Increased Prevalence of Focal Segmental Glomerulosclerosis

Manas Pustake, MD, is a resident in internal medicine at Texas Tech University.

Pustake highlights the reticence with which clinicians should approach providing platelet transfusion to patients.

Platelet Transfusion Raises Mortality Risk in Consumptive Thrombocytopenia, with Manas Pustake, MD

Study findings highlight the prevalence of steroid use in IBD care and identify key subgroups at higher risk of exposure.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Ulcerative Colitis

Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.

Young Women With Ulcerative Colitis Face Higher Corticosteroid Exposure Risk

Chair of The Christ Hospital Heart and Vascular Institute

Kereiakes discusses the potential of lerodalcibep for adults with hypercholesterolemia and high LDL-C, highlighting recent FDA approval. 

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Lerodalcibep’s FDA Approval For Hypercholesterolemia With Dean Kereiakes, MD

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Discover the latest advancements in diabetes treatment with retatrutide, a promising triple agonist showing significant weight loss and pain relief.

Type 2 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Osteoarthritis

On the HCPLive osteoarthritis page, resources on the topics of medical news and expert insight into OA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on degenerative joint disease, and more.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Diabetes Dialogue: Reacting to Retatrutide and TRIUMPH-4 Topline Data

chief medical officer of Intra-Cellular Therapies

New phase 3 data support the FDA approval of lumateperone, showing early efficacy and favorable tolerability as an adjunctive treatment for MDD.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Phase 3 Data Bolster FDA Approval of Lumateperone as Adjunctive MDD Therapy, With Suresh Durgam, MD

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Following the addition of a clinical study report to the NDA on December 12, the regulatory agency has extended the review period for the RASP inhibitor.

Ophthalmology

Ophthalmology page, resources on the topics of medical news and expert insight into ophthalmic disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on eye disease research, treatment, and drug development.

FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026

Investigators highlighted patterns of addictive behavior among those with chronic skin diseases in European tertiary dermatology centers.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Addictive Behaviors Linked with Chronic Skin Diseases Such as HS, Psoriasis

Sayna Norouzi, MD, is an assistant professor of medicine, clinical nephrologist, and founder and director of the glomerular disease and polycystic kidney disease clinics at Loma Linda University Medical Center.

This segment centers on the clinical development of atacicept, a BAFF/APRIL–pathway inhibitor designed to reduce the upstream production of galactose-deficient IgA1.

Video Series

Phase 2b and Phase 3 ORIGIN Trials of Atacicept in IgAN

Experts discuss innovative strategies for managing statin-intolerant patients, highlighting new therapies and the importance of individualized care.

Latest News

FDA Approves Depemokimab-ulaa (Exdensur) for Severe Asthma

Chronic Pain Associated With Significantly Reduced Ability to Relax Muscles

Skin of Color Savvy: Winter Skin Care for Patients of Color, With Heather Woolery-Lloyd, MD, and Aderonke Obayomi, MD, MPH

Efanesoctocog Alfa Improves Bleeding Regardless of Age in Hemophilia A, With Lynn Malec, MD, MSc

Global Data Suggest Increased Prevalence of Focal Segmental Glomerulosclerosis